Milan, Italy, 4 May 2022 – Enthera Pharmaceuticals (“Enthera”), a biotech company developing first-in-class biologics for selected autoimmune conditions based on the discovery of a novel apoptosis pathway, today announces the appointment of Aled Williams as Chief Executive Officer and member of its Board of Directors. Aled has over twenty-five years of experience as a senior […]
New publication titled ‘The IGFBP3/TMEM219 pathway regulates β-cell homeostasis’ published in leading peer-review journal, Nature Communications The research confirms that the recently discovered ‘IGFBP3/TMEM219’ apoptosis pathway plays a key role in beta cell homeostasis, and has the potential to be utilized as a new therapeutic approach for type 1 diabetes Enthera aims to leverage the IGFBP3/TMEM219 pathway to […]
https://www.entherapharmaceuticals.com/wp-content/uploads/2019/10/logo-300x85.png00entherahttps://www.entherapharmaceuticals.com/wp-content/uploads/2019/10/logo-300x85.pngenthera2022-02-03 16:40:572022-02-03 16:43:16Enthera Pharmaceuticals, Boston Children’s Hospital of the Harvard Medical School and the University of Milan reveal use of novel pathway to restore pancreatic cell function in diabetes in Nature Communications
Antonio Speziale joins Enthera with drug development and commercialization experience from roles at Galapagos, Shire, Novartis, Genzyme and Wyeth Milan, Italy, 4 October 2021 – Enthera Pharmaceuticals (“Enthera”), a biotech company developing first-in-class biologics for selected autoimmune conditions based on the discovery of a novel apoptosis pathway, has appointed Antonio Speziale as Chief Medical Officer. […]
https://www.entherapharmaceuticals.com/wp-content/uploads/2019/10/logo-300x85.png00entherahttps://www.entherapharmaceuticals.com/wp-content/uploads/2019/10/logo-300x85.pngenthera2021-10-04 09:05:202021-10-06 10:32:16Enthera Pharmaceuticals appoints Antonio Speziale as Chief Medical Officer
Enthera Pharmaceuticals Appoints Aled Williams as Chief Executive Officer
/in Press ReleasesMilan, Italy, 4 May 2022 – Enthera Pharmaceuticals (“Enthera”), a biotech company developing first-in-class biologics for selected autoimmune conditions based on the discovery of a novel apoptosis pathway, today announces the appointment of Aled Williams as Chief Executive Officer and member of its Board of Directors. Aled has over twenty-five years of experience as a senior […]
Enthera Pharmaceuticals, Boston Children’s Hospital of the Harvard Medical School and the University of Milan reveal use of novel pathway to restore pancreatic cell function in diabetes in Nature Communications
/in Press ReleasesNew publication titled ‘The IGFBP3/TMEM219 pathway regulates β-cell homeostasis’ published in leading peer-review journal, Nature Communications The research confirms that the recently discovered ‘IGFBP3/TMEM219’ apoptosis pathway plays a key role in beta cell homeostasis, and has the potential to be utilized as a new therapeutic approach for type 1 diabetes Enthera aims to leverage the IGFBP3/TMEM219 pathway to […]
Enthera Pharmaceuticals appoints Antonio Speziale as Chief Medical Officer
/in Press ReleasesAntonio Speziale joins Enthera with drug development and commercialization experience from roles at Galapagos, Shire, Novartis, Genzyme and Wyeth Milan, Italy, 4 October 2021 – Enthera Pharmaceuticals (“Enthera”), a biotech company developing first-in-class biologics for selected autoimmune conditions based on the discovery of a novel apoptosis pathway, has appointed Antonio Speziale as Chief Medical Officer. […]